MediPharm Labs Reports Positive Q2 2026 Net Income and Second Consecutive Quarter of Positive Adjusted EBITDA

TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS ) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three and six months ended June 30, 2026 (“Q2 2026”).

A welcome email is on its way. If you don't see it, please check your junk folder.

The Company improved sequentially on revenue, gross margin and Adjusted EBITDA versus the three months ended March 31, 2026 (“Q1 2026”). MediPharm Labs generated Adjusted EBITDA 1 of $0.9 million in Q2 2026, its strongest quarterly Adjusted EBITDA performance since 2019 2 and its second consecutive quarter of positive Adjusted EBITDA.

“Q2 demonstrates the strength and resilience of the MediPharm platform. We delivered our strongest quarterly Adjusted EBITDA since 2019 and returned to positive net income despite reimbursement and regulatory headwinds across several of our key markets. These results reflect the actions we have taken over the past six months to improve profitability, diversify revenue streams and build a stronger business.

At the same time, the positive Phase II LiBBY results highlight the unique value of our pharmaceutical capabilities and proprietary cannabinoid formulations. Together, these achievements demonstrate the strength of our commercial platform today and the long-term potential of MediPharm to help advance evidence-based cannabinoid medicines for patients with significant unmet needs.”